WAYFINDER: A PHASE 3B, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TEZEPELUMAB IN REDUCING ORAL CORTICOSTERIODS (OCS) USE IN OCS-DEPENDENT PATIENTS WITH SEVERE ASTHMA.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request